Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

UM Spinoff Lycera Starts Drug Trials; is Sale of Company Next?

Tuesday, April 05, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Lycera Corp., a University of Michigan spinoff developing drugs that target cancer and diseases of the immune system, has started human trials that could lead to the sale of the company next year.In December, the company finished a phase 1 U.S. Food and Drug Administration study that showed a compound with the working name of LYC-30937, which targets ulcerative colitis, is safe and well-tolerated by patients.

 

Read more.


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership.com®  ::  Legal